CUTANEOUS MELANOMA

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…

This Phase 3 trial tests a one-time cell therapy called IMA203 for people with advanced melanoma that has not responded to prior treatment. IMA203 is made from a patient's own immune cells and is designed to target cancer cells. The study compares IMA203 to standard treatments li…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, …

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests whether people with melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed with clear margins. About 1,749 adults with stage pT1b to pT4b melanoma will be randomly assigned to either standard follow-up care including re-excisi…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest…

This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their …

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This study tests whether adding a prebiotic-rich diet to standard immunotherapy before surgery can improve immune response in people with melanoma. About 35 adults with resectable melanoma will receive prebiotic snack packs and diet counseling alongside their usual treatment. The…

This early-phase trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has not responded to prior treatments. The main goals are to check safety and find the best dose. About 15 participa…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and how safe they are. About 33 adults whose melanoma worsened …

This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. T…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …

This study looks at how lifestyle factors like diet, exercise, mental health, and social support affect quality of life and outcomes in people with melanoma. Researchers will follow 5,000 participants over time using surveys and medical records. The goal is to gather knowledge th…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults before and after treatment to see how immun…

This study is investigating why some melanomas stop responding to immunotherapy. Researchers will take biopsies from 20 patients with advanced melanoma before and after treatment to see how tumor metabolism changes. The goal is to understand resistance mechanisms and find new way…

This observational study in Italy will examine the link between work-related sun exposure and melanoma. Researchers will interview 300 people (120 with melanoma, 180 without) about their job history, sun habits, and protection use. The goal is to better understand how outdoor wor…

This study follows 300 adults with advanced melanoma who are receiving immune checkpoint inhibitors. Researchers will collect blood samples, quality-of-life surveys, and medical records to track symptoms over time. The goal is to identify patterns and risk factors for worse sympt…

This study tests whether eating dried chicory root (a high-fiber prebiotic) every day for 6 weeks can change gut bacteria and immune cells in 20 people who had surgery for stage II melanoma. Researchers want to see if it increases helpful substances called short-chain fatty acids…